FULC Q2 2022 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-57.0% YoY

Gross Profit

-$23M-1229.4% margin

Operating Income

-$34M-1819.1% margin

Net Income

-$34M-1810.3% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

-27.4%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$29M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$195M

Total Liabilities

$34M

Stockholders' Equity

$161M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-57.0%
Gross Profit	-$23M	-$13M	-78.0%
Operating Income	-$34M	-$20M	-73.9%
Net Income	-$34M	-$20M	-73.4%